Introduction 69 70
Controversy surrounding whether or not menopausal hormone treatment (MHT) slows 71 progression of cardiovascular disease reflects, in part, differences among studies in 72 experimental design (timing of initiation of hormone treatment, doses and formulations) and co-73 existing cardiovascular risk factors of the population or study participants (4, 6, 16, 22, 24, 30, 74 33 ). In addition, potential benefit of MHT against development of atherosclerosis is offset by 75 potential risk of venous thrombosis especially in women with genetic variation in factors 76 associated with coagulation which may be more pronounced with the use of oral compared to 77 transdermal estrogen products and the impact of the oral products on liver metabolism (8, 9, 12, 78 35 ). In addition, several studies have implicated genetic variants in estrogen receptors with 79 progression of cardiovascular disease and venous thrombosis in men and women (1, 23, 34) . 80
However, estrogen receptor polymorphisms were not associated with adverse cardiovascular 81 outcomes in women randomized to oral conjugated equine estrogens in the Women's Health 82 Initiative (31) . Therefore, much remains to be learned about phenotypic expression of 83 polymorphisms in genes associated with estrogen responsiveness and thrombotic capacity in 84 evaluating potential benefits and risk of MHT in postmenopausal women. 85
The Kronos Early Estrogen Prevention Study (KEEPS) was designed to evaluate the 86 effects of MHT on progression of cardiovascular disease defined by quantitative changes in 87 carotid artery intima-medial thickness (CIMT) and coronary artery calcification (CAC), accepted 88 measures of subclinical atherosclerosis. A targeted candidate genetic analysis demonstrated 89 no association of genetic polymorphisms in estrogen receptors α or β with the absolute value of 90 either CIMT or CAC in women enrolled in KEEPS prior to randomization to treatment. Of the 91 polymorphisms of genes within the anticoagulant, procoagulant, fibrinolytic or innate immunity 92 pathways, only polymorphisms of genes within the innate and humoral immunity pathways were 93 associated with the baseline absolute value of CIMT or CAC, respectively (26) . However, at the 94 time of that study, women had transitioned into menopause and were estrogen depleted (serum 95 17β estradiol <40pg/mL). Thus, it remains to be determined whether estrogen treatments alter 96 these associations. Therefore, associations of genetic variants within the same targeted 97 candidate genes were evaluated with progression (i.e. change in measures) of subclinical 98 atherosclerosis following randomization to either active estrogen treatments or placebo for four 99 years. Two hypotheses were considered in these analyses: 1) genetic markers would be 100 associated with change in CIMT or CAC after the 4 years independent of treatment, and, 2) 101 there would be pharmacogenomic effects of genes with respect to change in CIMT or CAC after 102 application of treatment or placebo (i.e. genetic markers will modify the effects of the 103 treatment/placebo on CIMT and CAC progression.) 104 previously, the mean coefficient of variation between these two readings was 0.6% (SD, 0.7 147 [range, 0.0% to 7.7%]) (14) 148
Statistical analysis: Clinical characteristics were summarized at baseline and 4 years 149 separately, changes in clinical characteristics between baseline and the 4-year measurement 150 were tested using Wilcoxon Signed Rank tests. The analysis consisted of two outcomes, 4-year 151 change in CIMT as a continuous measure and 4-year change in CAC as a binary measure 152
[change > 5 vs. ≤5 Agatston Units (AU)]. CIMT was measured at yearly intervals for 4 years, 153
and modeling all 4-years of measurements yielded similar conclusions (data not shown). CAC 154 was measured at baseline and at year 4. First, the relationships of the two outcomes (CIMT 155 and CAC) and conventional cardiovascular risk variables were tested using linear regression 156 and logistic regression, respectively. None of these variables were significantly correlated with 157 the outcomes after multiple testing correction (data not shown), and were not adjusted for in 158 subsequent genetic analyses. However, percentage of European ethnicity was adjusted for in 159 subsequent genetic analyses to address possible population stratification. Previously, we had 160 established using ancestry informative markers that most KEEPS participants were Caucasian 161 and we used percentage CEU ancestry from the STRUCTURE program to estimate the 162 proportion of European ancestry within each individual (26). STRUCTURE allows for population 163 admixture and assigns individuals in the sample of interest (the KEEPS sample) population 164 probabilities. The technique assumes the loci are unlinked and it assumes Hardy-Weinberg 165 equilibrium within the populations. 166
Two genetic analyses were considered for each outcome, first testing for SNP effects on 167 the outcomes, and secondly testing for SNP*treatment interactions (i.e., SNP affecting the 168 relationship of the treatment and outcome, a pharmacogenomic effect). In both analyses, SNPs 169 (as count of minor allele) were used to model change in CIMT and change in CAC, via linear 170 and logistic regression, respectively. In the case of the pharmacogenomic analysis, a treatment 171 main effect and treatment*SNP interaction were also modeled with the treatment*SNP 172 interaction being tested with a likelihood ratio test. To correct for multiple testing we estimated 173 the effective number of independent tests and using the Bonferroni method we set our threshold 174 of significance at p<7. 73E-06 (11). 175 To test the overall association of SNPs in each of 4 genetic pathways (anticoagulant, 176 procoagulant, fibrinolysis, and innate immunity; a complete list of SNPs was published 177 previously (26)), a global test of the genetic variation in each pathway was conducted modeling 178
4-year change in CIMT or CAC by pathway SNPs using random effects models and testing all 179 SNPs in a pathway simultaneously with a likelihood ratio test (13) . 180
To the test the overall pharmacogenomic effect of pathways of SNPs on change in CAC 181 and CIMT, the Principle Components (PC)-gamma method was used (3). Principal components 182 were formed from SNPs within each gene, and enough principal components were retained for 183 each gene to explain 80% of the variation in SNPs within that gene. Then gene level tests were 184 conducted for each gene using F-tests of all treatment interactions with PCs retained in a 185 regression model for the continuous change in CIMT; and likelihood ratio test for all treatment 186 interactions with PCs retained in a logistic regression model of dichotomized change in CAC. 187
Fisher's p-value combination method was then used to generate a test statistic for the pathway. 188
Since genes in a pathway may be correlated to some degree, an asymptotic test was not used; 189 instead, a parametric bootstrap approach was applied (7) to obtain a pathway level p-value. 190 Briefly, we fit a null model without the PC*treatment interactions and for each individual 191 calculated their fitted value. Next, a bootstrap sample of participants was taken with 192 replacement, and a set of new CIMT or CAC values was simulated for the individuals in the 193 sample. This process was repeated to generate 1000 bootstrap samples under the null 194 hypothesis on no treatment-gene interactions. Each of these 1000 datasets was analyzed using 195 the PC-gamma method to obtain an empirical distribution of test statistics for the gene-treatment 196 interaction at the pathway level under the null hypothesis. The observed pathway test statistic 197 was then compared to this empirical null distribution, with the p-value being the fraction of 198 empirical test-statistic values that were greater than or equal to the observed test-statistic. All 199 analyses were performed in R v2.14.0. 200
Results 201
Clinical phenotypic characteristics of women for whom SNP analyses were performed 202 over the four years of treatment are shown in Table 1 . 203
CIMT 204
Independent of treatment: Mean CIMT increased over the four years of the study with variability 205 increasing with time ( Figure 1 ). To evaluate these increases two analyses were performed: one 206 examining only the change in CIMT from baseline to 4 years and the second considering 207 simultaneously all measures of CIMT over 4 years that included data of women with readings at 208 multiple time points (longitudinal analysis). Results of these two analyses were similar, so for 209 clarity, only changes from baseline to 4 years are presented here. None of the conventional 210 cardiovascular risk factors (Table 1) found to be associated with changes in CIMT at 4 years (data not shown). The relationship 212 between SNPs and the change in CIMT, adjusting for percentage European ancestry for an 213 individual, did not identify any significant associations after correcting for the number of SNPs 214 tested (Table 2, and Table 3 ). None of the SNPs previously reported to be associated with the 215 absolute value of CIMT at baseline (i.e. prior to hormone treatment) (21) were here found to be 216 associated with the change in CIMT after treatment. Furthermore, adjusting for baseline CIMT 217 did not affect the outcomes. 218
Pharmacogenomic effect of SNPs on the relationship of treatment and changes in CIMT at 4 219
years. Of women with DNA for analysis, 403 completed the study in their assigned treatment 220 group. Based on the P-value cutoff (see Methods), there were no statistically significant signals 221 for any particular SNP with a pharmacogenomic effect (data not shown); however, SNPs in the 222 innate immunity pathway had an overall pharmacogenomic effect on 4-year change in CIMT 223 (interaction of SNPs in the genetic pathway and treatment) in these women (P < 0.001, Table  224 3). We also observed that the SNPs effects on the 4 year change in CIMT varied by treatments 225 (i.e. presence of common or rare allele within transdermal 17β-estradiol or conjugated equine 226 estrogens groups) compared to placebo (Table 4 and fasting blood glucose, triglycerides and diastolic blood pressure (Table 5 ). However, only 233 baseline CAC appeared to be associated with change in CAC > 5 AU (P < 0.001) after 234 correcting for all of the generally accepted risk factors and was included as an adjustment factor 235 in subsequent genetic analyses. 236
Using a stepwise algorithm of clinical variable effects in multivariable logistic models, the 237 "best" predictive model for change in CAC included baseline CAC>0 AU (P < 2e-16), baseline 238 triglycerides (P = 0.009), baseline weight (p = 0.03), and change in CIMT (4 yr-baseline; P = 239 0.04). 240
The relationship between SNPs and change in CAC was modeled first using multiple 241 logistic regression, with adjustment for percentage European ancestry and baseline CAC > 0 242 (data not shown). None of the SNPs associated with changes of CAC > 5 AU after 4 years 243 (Table 6) were among the SNPs of interest based on association with the absolute AU score for 244 CAC prior to treatment (21). 245
Pharmacogenomic effect of SNPs on the relationship of treatment to changes in CAC at 4 246
years. In those women who completed the trial in their assigned treatment group or placebo 247 over the 4 years (n=403), and after adjusting for ethnicity and CAC > 0 AU, there was little 248 evidence for a SNP by treatment interaction effect (Table 7) . Genes not within the innate 249 immunity pathway that showed nominal significance for a pharmacogenomics effect of 250 treatment on CAC were SERAPINE 2 and beta adrenergic receptor 2 (ADRB2), respectively 251 (Table 7) . 252
253
Discussion 254 Changes in CIMT and CAC, the main outcomes of KEEPS, were not significantly altered 255 by either oCEE or tE2 compared to placebo over the 4 years of the study (14) . In the present 256 study, a targeted candidate gene analysis provides insight into processes contributing to these 257 main outcomes by identifying significant gene-by-treatment interactions in the progression of 258 CIMT but not CAC. 259 CIMT increases with age and time past menopause (38). The absence of association of 260 increases in CIMT with conventional risk factors most likely reflects the narrow range for most of 261 these variables (Table 1) and, in particular, mean systolic blood pressure did not differ 262 significantly from baseline to year 4 and was within what would be considered clinically a 263 "normative" range. Variability in progression of CIMT reflects in part natural aging processes 264 reflected by chronological and menopausal age, treatment assignment and gene/treatment 265 interactions. 266
Genes of the innate immunity pathway associated with the absolute value of CIMT at 267 baseline prior to randomization to treatment (26). Using pathway analysis, the innate immunity 268 pathway associated with pharmacogenomic effects of the hormone treatments on changes in 269 CIMT. Although individual SNPs did not achieve statistical significance with the change in 270 CIMT, the SNPs altered the treatment effect ( Figure 2 ). Depending upon the mean allele 271 frequency in the population, the penetrance of this pharmacogenomic effect would manifest as 272 increased variance in the phenotype (Figure 1 ) and reduce the ability to differentiate among 273 groups, a result consistent with the cumulative analysis of the KEEPS cohort (14) . 274
Other studies have identified associations of genes related to the immunity pathway with 275 increases in CIMT (37). However, some genome-wide association studies fail to identify genes 276 associated with increases in CIMT, which may reflect that these studies do not perform 277 hormone stratified analysis nor account for sex as a dichotomous variable in the analysis. (28). 278
Apolipoprotein E 4 (ApoE4) was shown to be associated with CIMT in several studies (21) but 279 unfortunately, this gene/SNP was not tested in the present study. Examining ApoE4 might be 280 interesting as this gene/SNP has greater critical risk factor for Alzheimer's disease in women 281 compared to men (29) and a sex differential of this gene/SNP in association with other 282 phenotypes would be interesting to explore. 283
Although fasting blood glucose, triglycerides and diastolic blood pressure associated 284 with CAC in univariate analysis, these conventional cardiovascular risk factors did not remain 285 significant after correction for multiple testing, which may reflect that the KEEPS participants 286
were relatively healthy women with conventional cardiovascular risk factors within normative 287 ranges. The first two variables relate to energy utilization while diastolic blood pressure may 288 reflect general arterial stiffening/reduced compliance in post-menopausal women (10, 27, 36) 289 and may become more relevant with aging. 290
One gene not within the innate immunity pathway that showed nominal association with 291 CAC, SERPINE2, may impact the coagulation cascade as this gene encodes a protein that 292 inhibits thrombin and urokinase plasminogen activator type 2. In addition, the adrenergic 293 system may impact CAC as changes in beta adrenergic receptors are associated with changes 294 in total peripheral resistance in women after menopause and variants in the receptor are 295 implicated in response to beta adrenergic blockers used in the treatment of hypertension (2, 20) . 296
Conventional risk factors such as hypertension, hypercholesterolemia and Type 2 Diabetes 297 (T2D) exacerbate accumulation of calcium in the coronary arteries. In expression of complex 298 traits, and despite the weak genetic effects, certain genetic variants in metabolic or immune 299 pathways may become more important mechanisms of disease progression. For example, 300 persons with T2D, CAC negatively correlated with variants in CD40 (5). Also, in women 301 screened for KEEPS, 14% were excluded based on CAC without other risk factors (25), 302 suggesting that in women, at least, coronary calcification may have several etiologies. 303
This study has several limitations. The study included a small number of mostly 304
Caucasian women who were at low risk for cardiovascular disease. It would be interesting to 305 observe these women over a longer time-course, even in the absence of hormone treatment, to 306 determine whether the same or different SNPs associate with disease progression with aging. 307
Serum levels of hormones were not consistently above that defining menopause for women 308 randomized to treatment and different associations might be found if serum levels of estrogen 309 were increased further. As in the previous analysis, polymorphisms in estrogen receptors did 310 not associate with either phenotype. Estrogen response elements reside in the promoter 311 regions of many genes and affect gene expression, which was not measured in the present 312 study. Influences of MHT on gene expression would be expected to differ among formulations 313
given that the metabolites of estrogen have differing binding affinity for estrogen receptors. In 314 the present study, the differential expression of genes with the SNPs of interest in response to 315 estrogen determined the contribution of those including perhaps those regulated by estrogen 316 and the phenotype. Additional work is needed to understand how polymorphisms in estrogen 317 receptors contribute to development of cardiovascular disease in women. 318
The magnitude of the pharmacogenomics effects differed by type of MHT. It is unlikely 319 that methodological variability in measurement of CIMT contributed to the pharmacogenomic 320 effects as methods to obtain the ultrasound scans were standardized, performed by trained 321 personnel and coefficient of variations between two scans obtained prior to randomization was 322 <1%. Power to detect pharmacogenomic effects on change in CAC was limited by the small 323 number of women with changes of CAC >5 Agatston Units, as the approach that was used to 324 assess significance of treatment-by-gene interactions at the pathway level (PC-Gamma method 325 with the parametric bootstrap) is expected to have low power for evaluating association with 326 dichotomous outcomes when the number of cases is small. Finally, the study used a candidate 327 gene approach specifically to investigate genes related to coagulation and immunity to evaluate 328 the genetic components of MHT and thrombotic risk. Other pathways may have been 329 discovered with a genome wide association approach. 330
In spite of these limitations, the results of this study emphasize that in genetic 331 association studies of complex disease traits, it is critical to account for sex and hormonal status 332 of the study participants. In addition, this analysis provides value to the scientific community as 333 it is the first study to identify pharmacogenomic effects of MHT on vascular remodeling and 334 thus, provides insight into why there is variability in cardiovascular effects of MHT in women. box is the 25 th and 75 th percentile range; vertical lines represent the 1.5 interquartile range 580 (IQR); points outside the IQR are plotted as is (outliers). Upper panel: r11466536 for gene 581 TGFBR2, transforming growth factor beta receptor 2 binding transforming growth factor beta, 582 the complex phosphorylates proteins and acts as a transcription factor regulating cell 583 proliferation; Middle panel: r1569723 for gene CD40, a protein of the tumor necrotic factor 584 superfamily of receptors involved in triggering immunological activation; Bottom panel: r261060 585 for gene DOCK2, dictator of cytokinesis 2, encodes a protein involved with small G-protein 586 coupled intracellular signaling. Although these individual SNPs within the innate immunity 587 pathway did not reach statistical significance, the overall pathway analysis which represents the 588 collective analysis of all of the genes/SNPS included in this study did reach statistical 589 significance. 590 *next to LOC100128028; **next to LOC390503; + next to FFAR1; ++ next to LOC100129171 NA = no results due to small sample size. Abbreviations: E2, transdermal 17β estradiol; CEE, oral conjugated equine estrogen; MAF, mean allele frequency. * AU=Agatston Units
